Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Barbara Burtness MD
Barbara Burtness MD Advisory Board
Oliver Sartor MD
Oliver Sartor MD Advisory Board
Jeffrey Kirshner MD, FACP, FASCO
Jeffrey J. Kirshner MD, FACP, FASCO Advisory Board
See All Experts
Published in Oncology

Journal Scan / Research · June 29, 2024

Dose-Escalation Trial of Taselisib (GDC-0032) Plus HER2-Directed Therapies for Advanced HER2+ Breast Cancer

ESMO Open

 

 Save  Recommend
 Share

Additional Info

ESMO Open
Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer
ESMO Open 2024 Jun 03;9(6)103465, A Grinshpun, S Ren, N Graham, MK DeMeo, E Wrabel, J Carter, N Tayob, A Pereslete, E Hamilton, D Juric, EL Mayer, SM Tolaney, IE Krop, O Metzger

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated